Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

News Conference News AHA 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

November 12, 2025

Starting SGLT2 inhibitors in the Hospital for Acute HF Gains Support

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

August 30, 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

News Conference News ESC Heart Failure 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

May 20, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

News Conference News THT 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

February 19, 2025

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Debating the Role of T-TEER in the Sickest Patients

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

September 01, 2023

Early SGLT2 Inhibition, Spot Urine Sodium Checks May Help in Acute HF

News Conference News ESC 2023

Early SGLT2 Inhibition, Spot Urine Sodium Checks May Help in Acute HF

September 01, 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

August 30, 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

August 25, 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

March 09, 2023

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

News Conference News HFSA 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

October 04, 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

August 27, 2022

Dapagliflozin Boosts Health Status Across LVEF Range

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

May 23, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.